PRIOR AUTHORIZATION BYPASS Tanzeum (albiglutide) Bypass the Prior Authorization by Modifying the following Prescription Forms to the Patient's Needs

Similar documents
PRIOR AUTHORIZATION BYPASS Bydureon (long acting exenatide)

SAMPLE IgE: ESR: CRP: # Joints: %BSA: Height: Weight: BMI:

Drug Class Review Newer Diabetes Medications and Combinations

Deaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015

Collaborative Practice Agreement

DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0

Date of Review: September 2016 Date of Last Review: September 2015

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018

Non-Insulin Diabetes Medications Summary

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol

STEP THERAPY CRITERIA

The Death of Sulfonylureas? A Review of New Diabetes Medications

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical

GLYXAMBI (empagliflozin-linagliptin) oral tablet

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

Physician Drug Reference Chart for Diabetes Antidiabetic Medications

SGLT2 Inhibitors

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics

1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

What s New in Diabetes Treatment. Disclosures

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Disclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017

SGLT2 Inhibitors

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

Diabetes Mellitus II CPG

Understanding Your Diabetes: A Basic Guide

What s New in Diabetes Medications. Jena Torpin, PharmD

SGLT2 Inhibitors

Pharmacologic Agents for Treatment of Type 2 Diabetes

Table 1. Antihyperglycemic agents for use in type 2 diabetes

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol

Diabetes Treatment Guidelines

TYP 2 DIABETES. Marc Donath

Diabetes Medications: Oral Anti-Hyperglycemic Medications

Very Practical Tips for Managing Type 2 Diabetes

Oral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action

Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018

Diabetes 2016: Strategies for achieving optimal diabetes control

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

Oral and Injectable Non-insulin Antihyperglycemic Agents

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Multiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014

Update Diabetes Therapie. Marc Y Donath

Diabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System

How can we improve outcomes in Type 2 diabetes?

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents

Advanced Practice Education Associates. Endocrine

First Name. Specialty: Fax. First Name DOB: Duration:

Newer Therapies for Type 2 Diabetes

Halting the Rise, Newest Non- Insulin Options for Lowering A1c

Halting the Rise, Newest Non- Insulin Options for Lowering A1c

Glycemic Management of Type 2 Diabetes. Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University

3. Does the patient meet ALL of the following requirements? Y N

First Name. Specialty: Fax. First Name DOB: Duration:

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

Diabetes management in liver and kidney disease

Current and future market dynamics overview

SGLT2 Inhibitors

Diabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Glucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria

Feidhmeannacht na Seirbhíse Sláinte

See Important Reminder at the end of this policy for important regulatory and legal information.

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol

3. Cardiovascular Disease?

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

2. Does the member have a diagnosis of central precocious puberty? Y N

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

Welcome to the PHASE Learning Community! October 31, 2018

Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes

Request for Special Authorization Enbrel

DM Fundamentals Class 4 Meds for Type 2

Formulary Medical Necessity Program

Navigating the New Options for the Management of Type 2 Diabetes

Pharmacy Prior Authorization

2. Is this request for a preferred medication? Y N

2/9/2016. The Evolving Armamentarium for Type 2 Diabetes: Incorporating New Classes in the Treatment of Our Patients. Objectives: Pharmacists

3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Dept of Diabetes Main Desk

ORAL AND INJECTABLE (NON-INSULIN) PHARMACOLOGICAL AGENTS FOR TYPE 2 DIABETES

Pharmacy Prior Authorization

Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: Last Review Date: 02.

2/17/2016. Objectives. Define. Hey Sugar! DMII Management in Hospice Care

Cardiovascular Impact of Medications for Treating Type 2 Diabetes

2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?

See Important Reminder at the end of this policy for important regulatory and legal information.

New Therapies for Diabetes

DM Fundamentals Class 4 Meds for Type 2

Managing Complex Diabetes Cases: Medication Update. Celia Levesque MSN, RN, CNS-BC, CDE, BC-ADM

Transcription:

Please ote: Medical ecessity Prior Authorization may be overrided for both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager. PRIOR AUTHORIZATIO BPASS Tanzeum (albiglutide) Bypass the Prior Authorization by Modifying the following Prescription Forms to the Patient's eeds Drug ame Refer for Diabetes/ Insulin Protocol COMPLETE PRIOR AUTHORIZATIO FORMS: as directed by physician Dx: DIABETES ICD 10: E 11.9 SAMPLE

Prescriber Information Last ame: DEA/PI: Specialty: Phone Fax Member Information Last ame: Member ID umber DOB: Medication Information: Drug ame and Strength: Diagnosis: Quantity and Dosing: Duration: When advised below, please include all requested fax documentation (lab results, etc.) when submitting this Prior Authorization fax form; not submitting requested documentation could delay the clinical review process. Tanzeum Prior Authorization Form ou must answer ALL of the following questions 1. Has the patient had a trial and failure or intolerance to Victoza, Byetta, or Bydureon? Please submit documentation 2. Does the patient have a diagnosis of type 2 diabetes? 3. Is the patient 18 years of age or older? 4. Does the patient have gastroparesis? 5. Has the patient been on this therapy previously? 6. Is the patient s HbA1c greater than 6.9%? HbA1c must be taken within the past 6 months and documentation is required 7. Was the patient s HbA1c greater than 6.9% prior to starting therapy? Documentation is required 8. Has the patient had a trial and an inadequate response or intolerance to a sulfonylurea? 9. Does the patient have a contraindication to therapy with a sulfonylurea (i.e., debilitated state, past history of falls, high risk for falls, hepatic insufficiency)? 10. Is the patient currently taking and will he/she continue to take a sulfonylurea? If no, please provide rationale for discontinuing therapy: 11. Has the patient had a trial and an inadequate response or intolerance to metformin? Page 1 of 3

12. Does the patient have a contraindication to therapy with metformin (i.e., renal insufficiency, hepatic insufficiency)? 13. Is the patient currently taking and will he/she continue to take metformin while on Tanzeum therapy? If no, please provide rationale for discontinuing therapy: 14. Is the patient currently taking any of the following medications? (Please Circle) Precose (acarbose) Byetta, Bydureon (exenatide) Symlin (pramlintide) esina (alogliptin) Jentadueto (linagliptin / metformin) Kombiglyze XR (saxagliptin / metformin) Farxiga (dapagliflozin) Kazano (alogliptin / metformin) Invokamet (canagliflozin / metformin) Trulicity (dulaglutide) Glyset (miglitol) Tradjenta (linagliptin) Xigduo XR (dapagliflozin-metformin) Januvia (sitagliptin) Onglyza (saxagliptin) Oseni (alogliptin / pioglitazone) Victoza (liraglutide) Invokana (canagliflozin) Jardiance (empagliflozin) Janumet/Janumet XR (sitagliptin / metformin) 15. If the patient is taking any of the following medications, will concomitant therapy with those agents be discontinued? Precose (acarbose) Byetta, Bydureon (exenatide) Symlin (pramlintide) esina (alogliptin) Jentadueto (linagliptin / metformin) Kombiglyze XR (saxagliptin / metformin) Farxiga (dapagliflozin) Kazano (alogliptin / metformin) Invokamet (canagliflozin / metformin) Trulicity (dulaglutide) Glyset (miglitol) Tradjenta (linagliptin) Xigduo XR (dapagliflozin-metformin) Januvia (sitagliptin) Onglyza (saxagliptin) Oseni (alogliptin / pioglitazone) Victoza (liraglutide) Invokana (canagliflozin) Jardiance (empagliflozin) Janumet/Janumet XR (sitagliptin / metformin) Please note, not all drugs/diagnoses are covered on all plans. Page 2 of 3

Comments: Information given on this form is accurate as of this date. Prior Authorization forms are located on the Cover Page. Print a new form for each request as forms are updated periodically. Prescriber or Authorized Signature Date Authorized Medical Staff ame/title Attention Healthcare Provider: If you would like to discuss this request with a medical professional, please contact the Prior Authorization Department whose numbers appear on the Cover Page. I understand that USDoctor's use or disclosure of individually identifiable health information, whether furnished by me or obtained by another source such as medical providers, shall be in accordance with federal privacy regulations under HIPAA (Health Insurance Portability and Accountability Act of 1996). Page 3 of 3

Contact Information: Telephone: (855)251.9116 Fax: (248)593.9575 Please ote: Medical ecessity Prior Authorization may be utilized to override both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager. PRIOR AUTHORIZATIO FORM: COVER PAGE Plan Member ID Drug ame Quantity Directions Diagnosis MEMBER IFORMATIO DRUG IFORMATIO Last ame Date of Birth ICD-10 Duration of Therapy PLEASE LIST ALTERATIVE THERAPIES THAT HAVE BEE ATTEMPTED AD A OTHER PERTIET IFORMATIO RELATED TO DRUG AD/OR DISEASE STATE. IF OT PRESET, WITHI ORMAL LIMITS WILL BE USED FOR THE REVIEW. Medication/Failure Reason: IgE: ESR: CRP: # Joints: %BSA: Height: Weight: BMI: HA1C: Hemoglobin: Hematocrit: T-Score: Dialysis: Long Term Care Facility: Self Injecting: Stimulation test: / Growth velocity: #Chemotherapy cycles/month: Mini-Mental Status Test: Baseline Free testosterone/total testosterone: / HCV RA viral load: Viral Genotype: ALT: PHSICIA IFORMATIO Physician Signature Date Physician ame PI # Phone umber Action eeded Only mark Urgent when standard review time would seriously harm the member s life or health or ability to regain maximum function Fax umber Pharmacy Fax Urgent For Review The information contained in this facsimile message, including the attachments, may be privileged, may constitute inside information and is intended only for use of the addressee. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited and may be unlawful. If you have received this communication in error, please immediately notify me by replying to this message and destroy the original message.